Tight control in the vascular endotype of systemic sclerosis. Improving outcomes in pulmonary arterial hypertension associated with systemic sclerosis using personalized medicine, a predictive study.
Withdrawn
- Conditions
- 10003816pulmonale hypertensiepulmonary arterial hypertension associated to systemic sclerosis
- Registration Number
- NL-OMON44207
- Lead Sponsor
- Radboudumc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Fulfilling the ACR-Eular classification criteria of systemic sclerosis (15)
DLCO <80% of predicted
Age over 18 years
Exclusion Criteria
Diagnosis of pulmonary hypertension
Current treatment with endothelin receptor antagonists or angiotensin blokkers
Cyclophosphamide treatment or autologous stem cell transplantation
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Expected results and conclusions<br /><br>We hypothesize that in patients with a vascular endotype of SSc both the<br /><br>incidence of PAH and mortality due to PAH will be higher than in patients<br /><br>without this endotype. More intense screening algorithms will be applicable for<br /><br>these vascular endotype patients for early diagnosis and treatment. This will<br /><br>shed new light on the screening of PAH in SSc with risk stratification and<br /><br>appliance of personalized medicine and herewith early diagnosis of PAH, early<br /><br>implementation of targeted treatment, improving survival and saving costs. </p><br>
- Secondary Outcome Measures
Name Time Method <p>na</p><br>